Ovarian Cancer-Reference-Cited by-同舟云学术

Ovarian Cancer

Published:2019-03 Issue:1 Volume:46 Page:67-88
ISSN:0889-8545
Container-title:Obstetrics and Gynecology Clinics of North America
language:en
Short-container-title:Obstetrics and Gynecology Clinics of North America

Author:

Previs Rebecca Ann,Secord Angeles Alvarez

Funder

AbbVie

Amgen

Astellas Pharma

Astex Pharmaceuticals Inc

AstraZeneca

Boerhinger Ingelheim

Bristol-Myers Squibb

Endocyte

Genentech

Incyte

Merck

PharmaMar

TESARO

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference88 articles.

1. Cancer facts & figures 2018: special section: ovarian cancer. 2018. Available at: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html.

2. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer;Vergote;N Engl J Med,2010

3. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial;Kehoe;Lancet,2015

4. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome;Fagotti;Eur J Cancer,2016

5. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of non‐genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death;Cancer Reports;2023-11-27

2. New use of preoperative fibrinogen in ovarian cancer management;Translational Cancer Research;2023-11

3. Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer;Journal of Controlled Release;2023-08

4. Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR;Medicina;2023-03-19

5. CircBNC2 affects epithelial ovarian cancer progression through the miR-223-3p/LARP4 axis;Anti-Cancer Drugs;2022-11-17